Alzheimer Vaccines: Vaccines or candidate vaccines used to prevent or treat ALZHEIMER DISEASE.Alzheimer Disease: A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)Vaccines: Suspensions of killed or attenuated microorganisms (bacteria, viruses, fungi, protozoa), antigenic proteins, synthetic constructs, or other bio-molecular derivatives, administered for the prevention, amelioration, or treatment of infectious and other diseases.Vaccines, Inactivated: Vaccines in which the infectious microbial nucleic acid components have been destroyed by chemical or physical treatment (e.g., formalin, beta-propiolactone, gamma radiation) without affecting the antigenicity or immunogenicity of the viral coat or bacterial outer membrane proteins.Viral Vaccines: Suspensions of attenuated or killed viruses administered for the prevention or treatment of infectious viral disease.Vaccines, Combined: Two or more vaccines in a single dosage form.Vaccines, DNA: Recombinant DNA vectors encoding antigens administered for the prevention or treatment of disease. The host cells take up the DNA, express the antigen, and present it to the immune system in a manner similar to that which would occur during natural infection. This induces humoral and cellular immune responses against the encoded antigens. The vector is called naked DNA because there is no need for complex formulations or delivery agents; the plasmid is injected in saline or other buffers.Vaccines, Synthetic: Small synthetic peptides that mimic surface antigens of pathogens and are immunogenic, or vaccines manufactured with the aid of recombinant DNA techniques. The latter vaccines may also be whole viruses whose nucleic acids have been modified.Bacterial Vaccines: Suspensions of attenuated or killed bacteria administered for the prevention or treatment of infectious bacterial disease.AIDS Vaccines: Vaccines or candidate vaccines containing inactivated HIV or some of its component antigens and designed to prevent or treat AIDS. Some vaccines containing antigens are recombinantly produced.Vaccines, Subunit: Vaccines consisting of one or more antigens that stimulate a strong immune response. They are purified from microorganisms or produced by recombinant DNA techniques, or they can be chemically synthesized peptides.Vaccines, Conjugate: Semisynthetic vaccines consisting of polysaccharide antigens from microorganisms attached to protein carrier molecules. The carrier protein is recognized by macrophages and T-cells thus enhancing immunity. Conjugate vaccines induce antibody formation in people not responsive to polysaccharide alone, induce higher levels of antibody, and show a booster response on repeated injection.Vaccination: Administration of vaccines to stimulate the host's immune response. This includes any preparation intended for active immunological prophylaxis.Malaria Vaccines: Vaccines made from antigens arising from any of the four strains of Plasmodium which cause malaria in humans, or from P. berghei which causes malaria in rodents.Amyloid beta-Peptides: Peptides generated from AMYLOID BETA-PEPTIDES PRECURSOR. An amyloid fibrillar form of these peptides is the major component of amyloid plaques found in individuals with Alzheimer's disease and in aged individuals with trisomy 21 (DOWN SYNDROME). The peptide is found predominantly in the nervous system, but there have been reports of its presence in non-neural tissue.Papillomavirus Vaccines: Vaccines or candidate vaccines used to prevent PAPILLOMAVIRUS INFECTIONS. Human vaccines are intended to reduce the incidence of UTERINE CERVICAL NEOPLASMS, so they are sometimes considered a type of CANCER VACCINES. They are often composed of CAPSID PROTEINS, especially L1 protein, from various types of ALPHAPAPILLOMAVIRUS.Meningococcal Vaccines: Vaccines or candidate vaccines used to prevent infection with NEISSERIA MENINGITIDIS.Hepatitis B Vaccines: Vaccines or candidate vaccines containing inactivated hepatitis B or some of its component antigens and designed to prevent hepatitis B. Some vaccines may be recombinantly produced.Measles Vaccine: A live attenuated virus vaccine of chick embryo origin, used for routine immunization of children and for immunization of adolescents and adults who have not had measles or been immunized with live measles vaccine and have no serum antibodies against measles. Children are usually immunized with measles-mumps-rubella combination vaccine. (From Dorland, 28th ed)Pertussis Vaccine: A suspension of killed Bordetella pertussis organisms, used for immunization against pertussis (WHOOPING COUGH). It is generally used in a mixture with diphtheria and tetanus toxoids (DTP). There is an acellular pertussis vaccine prepared from the purified antigenic components of Bordetella pertussis, which causes fewer adverse reactions than whole-cell vaccine and, like the whole-cell vaccine, is generally used in a mixture with diphtheria and tetanus toxoids. (From Dorland, 28th ed)Haemophilus Vaccines: Vaccines or candidate vaccines containing antigenic polysaccharides from Haemophilus influenzae and designed to prevent infection. The vaccine can contain the polysaccharides alone or more frequently polysaccharides conjugated to carrier molecules. It is also seen as a combined vaccine with diphtheria-tetanus-pertussis vaccine.BCG Vaccine: An active immunizing agent and a viable avirulent attenuated strain of Mycobacterium tuberculosis, var. bovis, which confers immunity to mycobacterial infections. It is used also in immunotherapy of neoplasms due to its stimulation of antibodies and non-specific immunity.Poliovirus Vaccine, Inactivated: A suspension of formalin-inactivated poliovirus grown in monkey kidney cell tissue culture and used to prevent POLIOMYELITIS.Rabies Vaccines: Vaccines or candidate vaccines used to prevent and treat RABIES. The inactivated virus vaccine is used for preexposure immunization to persons at high risk of exposure, and in conjunction with rabies immunoglobulin, for postexposure prophylaxis.Rotavirus Vaccines: Vaccines or candidate vaccines used to prevent infection with ROTAVIRUS.Cholera Vaccines: Vaccines or candidate vaccines used to prevent infection with VIBRIO CHOLERAE. The original cholera vaccine consisted of killed bacteria, but other kinds of vaccines now exist.Amyloid beta-Protein Precursor: A single-pass type I membrane protein. It is cleaved by AMYLOID PRECURSOR PROTEIN SECRETASES to produce peptides of varying amino acid lengths. A 39-42 amino acid peptide, AMYLOID BETA-PEPTIDES is a principal component of the extracellular amyloid in SENILE PLAQUES.tau Proteins: Microtubule-associated proteins that are mainly expressed in neurons. Tau proteins constitute several isoforms and play an important role in the assembly of tubulin monomers into microtubules and in maintaining the cytoskeleton and axonal transport. Aggregation of specific sets of tau proteins in filamentous inclusions is the common feature of intraneuronal and glial fibrillar lesions (NEUROFIBRILLARY TANGLES; NEUROPIL THREADS) in numerous neurodegenerative disorders (ALZHEIMER DISEASE; TAUOPATHIES).Typhoid-Paratyphoid Vaccines: Vaccines used to prevent TYPHOID FEVER and/or PARATYPHOID FEVER which are caused by various species of SALMONELLA. Attenuated, subunit, and inactivated forms of the vaccines exist.Neurofibrillary Tangles: Abnormal structures located in various parts of the brain and composed of dense arrays of paired helical filaments (neurofilaments and microtubules). These double helical stacks of transverse subunits are twisted into left-handed ribbon-like filaments that likely incorporate the following proteins: (1) the intermediate filaments: medium- and high-molecular-weight neurofilaments; (2) the microtubule-associated proteins map-2 and tau; (3) actin; and (4) UBIQUITINS. As one of the hallmarks of ALZHEIMER DISEASE, the neurofibrillary tangles eventually occupy the whole of the cytoplasm in certain classes of cell in the neocortex, hippocampus, brain stem, and diencephalon. The number of these tangles, as seen in post mortem histology, correlates with the degree of dementia during life. Some studies suggest that tangle antigens leak into the systemic circulation both in the course of normal aging and in cases of Alzheimer disease.Smallpox Vaccine: A live VACCINIA VIRUS vaccine of calf lymph or chick embryo origin, used for immunization against smallpox. It is now recommended only for laboratory workers exposed to smallpox virus. Certain countries continue to vaccinate those in the military service. Complications that result from smallpox vaccination include vaccinia, secondary bacterial infections, and encephalomyelitis. (Dorland, 28th ed)Tuberculosis Vaccines: Vaccines or candidate vaccines used to prevent or treat TUBERCULOSIS.Antibodies, Viral: Immunoglobulins produced in response to VIRAL ANTIGENS.Chickenpox Vaccine: A live, attenuated varicella virus vaccine used for immunization against chickenpox. It is recommended for children between the ages of 12 months and 13 years.Diphtheria-Tetanus-Pertussis Vaccine: A vaccine consisting of DIPHTHERIA TOXOID; TETANUS TOXOID; and whole-cell PERTUSSIS VACCINE. The vaccine protects against diphtheria, tetanus, and whooping cough.Plaque, Amyloid: Accumulations of extracellularly deposited AMYLOID FIBRILS within tissues.Mumps Vaccine: Vaccines used to prevent infection by MUMPS VIRUS. Best known is the live attenuated virus vaccine of chick embryo origin, used for routine immunization of children and for immunization of adolescents and adults who have not had mumps or been immunized with live mumps vaccine. Children are usually immunized with measles-mumps-rubella combination vaccine.Hepatitis A Vaccines: Vaccines or candidate vaccines used to prevent infection with hepatitis A virus (HEPATOVIRUS).Immunization Schedule: Schedule giving optimum times usually for primary and/or secondary immunization.Adjuvants, Immunologic: Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity.Immunization, Secondary: Any immunization following a primary immunization and involving exposure to the same or a closely related antigen.Brain: The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM.Measles-Mumps-Rubella Vaccine: A combined vaccine used to prevent MEASLES; MUMPS; and RUBELLA.Streptococcal Vaccines: Vaccines or candidate vaccines used to prevent STREPTOCOCCAL INFECTIONS.Anthrax Vaccines: Vaccines or candidate vaccines used to prevent ANTHRAX.Dengue Vaccines: Vaccines or candidate vaccines used to prevent infection with DENGUE VIRUS. These include live-attenuated, subunit, DNA, and inactivated vaccines.Vaccines, Virosome: Vaccines using VIROSOMES as the antigen delivery system that stimulates the desired immune response.Immunization: Deliberate stimulation of the host's immune response. ACTIVE IMMUNIZATION involves administration of ANTIGENS or IMMUNOLOGIC ADJUVANTS. PASSIVE IMMUNIZATION involves administration of IMMUNE SERA or LYMPHOCYTES or their extracts (e.g., transfer factor, immune RNA) or transplantation of immunocompetent cell producing tissue (thymus or bone marrow).Viral Hepatitis Vaccines: Any vaccine raised against any virus or viral derivative that causes hepatitis.Poliovirus Vaccine, Oral: A live vaccine containing attenuated poliovirus, types I, II, and III, grown in monkey kidney cell tissue culture, used for routine immunization of children against polio. This vaccine induces long-lasting intestinal and humoral immunity. Killed vaccine induces only humoral immunity. Oral poliovirus vaccine should not be administered to immunocompromised individuals or their household contacts. (Dorland, 28th ed)Yellow Fever Vaccine: Vaccine used to prevent YELLOW FEVER. It consists of a live attenuated 17D strain of the YELLOW FEVER VIRUS.Apolipoprotein E4: A major and the second most common isoform of apolipoprotein E. In humans, Apo E4 differs from APOLIPOPROTEIN E3 at only one residue 112 (cysteine is replaced by arginine), and exhibits a lower resistance to denaturation and greater propensity to form folded intermediates. Apo E4 is a risk factor for ALZHEIMER DISEASE and CARDIOVASCULAR DISEASES.Antibodies, Bacterial: Immunoglobulins produced in a response to BACTERIAL ANTIGENS.Plague Vaccine: A suspension of killed Yersinia pestis used for immunizing people in enzootic plague areas.Fungal Vaccines: Suspensions of attenuated or killed fungi administered for the prevention or treatment of infectious fungal disease.Neurofibrils: The delicate interlacing threads, formed by aggregations of neurofilaments and neurotubules, coursing through the CYTOPLASM of the body of a NEURON and extending from one DENDRITE into another or into the AXON.Rubella Vaccine: A live attenuated virus vaccine of duck embryo or human diploid cell tissue culture origin, used for routine immunization of children and for immunization of nonpregnant adolescent and adult females of childbearing age who are unimmunized and do not have serum antibodies to rubella. Children are usually immunized with measles-mumps-rubella combination vaccine. (Dorland, 28th ed)Vaccines, Acellular: Vaccines that are produced by using only the antigenic part of the disease causing organism. They often require a "booster" every few years to maintain their effectiveness.Mice, Inbred BALB CSAIDS Vaccines: Vaccines or candidate vaccines designed to prevent SAIDS; (SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME); and containing inactivated SIMIAN IMMUNODEFICIENCY VIRUS or type D retroviruses or some of their component antigens.Salmonella Vaccines: Vaccines or candidate vaccines used to prevent infection with SALMONELLA. This includes vaccines used to prevent TYPHOID FEVER or PARATYPHOID FEVER; (TYPHOID-PARATYPHOID VACCINES), and vaccines used to prevent nontyphoid salmonellosis.Vaccines, Virus-Like Particle: Vaccines using supra-molecular structures composed of multiple copies of recombinantly expressed viral structural proteins. They are often antigentically indistinguishable from the virus from which they were derived.Dementia: An acquired organic mental disorder with loss of intellectual abilities of sufficient severity to interfere with social or occupational functioning. The dysfunction is multifaceted and involves memory, behavior, personality, judgment, attention, spatial relations, language, abstract thought, and other executive functions. The intellectual decline is usually progressive, and initially spares the level of consciousness.Ebola Vaccines: Vaccines or candidate vaccines used to prevent EBOLA HEMORRHAGIC FEVER.Presenilin-1: Integral membrane protein of Golgi and endoplasmic reticulum. Its homodimer is an essential component of the gamma-secretase complex that catalyzes the cleavage of membrane proteins such as NOTCH RECEPTORS and AMYLOID BETA-PEPTIDES precursors. PSEN1 mutations cause early-onset ALZHEIMER DISEASE type 3 that may occur as early as 30 years of age in humans.Amyloid Precursor Protein Secretases: Endopeptidases that are specific for AMYLOID PROTEIN PRECURSOR. Three secretase subtypes referred to as alpha, beta, and gamma have been identified based upon the region of amyloid protein precursor they cleave.Influenza, Human: An acute viral infection in humans involving the respiratory tract. It is marked by inflammation of the NASAL MUCOSA; the PHARYNX; and conjunctiva, and by headache and severe, often generalized, myalgia.Amyloid: A fibrous protein complex that consists of proteins folded into a specific cross beta-pleated sheet structure. This fibrillar structure has been found as an alternative folding pattern for a variety of functional proteins. Deposits of amyloid in the form of AMYLOID PLAQUES are associated with a variety of degenerative diseases. The amyloid structure has also been found in a number of functional proteins that are unrelated to disease.Cognition Disorders: Disturbances in mental processes related to learning, thinking, reasoning, and judgment.Antibodies, Neutralizing: Antibodies that reduce or abolish some biological activity of a soluble antigen or infectious agent, usually a virus.Staphylococcal VaccinesDiphtheria-Tetanus-acellular Pertussis Vaccines: Combined vaccines consisting of DIPHTHERIA TOXOID; TETANUS TOXOID; and an acellular form of PERTUSSIS VACCINE. At least five different purified antigens of B. pertussis have been used in various combinations in these vaccines.Cytomegalovirus Vaccines: Vaccines or candidate vaccines used to prevent infection with CYTOMEGALOVIRUS.Peptide Fragments: Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques.Immunization Programs: Organized services to administer immunization procedures in the prevention of various diseases. The programs are made available over a wide range of sites: schools, hospitals, public health agencies, voluntary health agencies, etc. They are administered to an equally wide range of population groups or on various administrative levels: community, municipal, state, national, international.Injections, Intramuscular: Forceful administration into a muscle of liquid medication, nutrient, or other fluid through a hollow needle piercing the muscle and any tissue covering it.

Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease. (1/58)

Alzheimer disease (AD) is characterized by the progressive deposition of the 42-residue amyloid beta protein (Abeta) in brain regions serving memory and cognition. In animal models of AD, immunization with Abeta results in the clearance of Abeta deposits from the brain. However, a trial of vaccination with synthetic human Abeta1-42 in AD resulted in the development of meningoencephalitis in some patients. We measured cellular immune responses to Abeta in middle-aged and elderly healthy subjects and in patients with AD. A significantly higher proportion of healthy elderly subjects and patients with AD had strong Abeta-reactive T cell responses than occurred in middle-aged adults. The immunodominant Abeta epitopes in humans resided in amino acids 16-33. Epitope mapping enabled the identification of MHC/T cell receptor (TCR) contact residues. The occurrence of intrinsic T cell reactivity to the self-antigen Abeta in humans has implications for the design of Abeta vaccines, may itself be linked to AD susceptibility and course, and appears to be associated with the aging process.  (+info)

Alzheimer's disease abeta vaccine reduces central nervous system abeta levels in a non-human primate, the Caribbean vervet. (2/58)

Amyloid beta (Abeta) protein immunotherapy lowers cerebral Abeta and improves cognition in mouse models of Alzheimer's disease (AD). Here we show that Caribbean vervet monkeys (Chlorocebus aethiops, SK) develop cerebral Abeta plaques with aging and that these deposits are associated with gliosis and neuritic dystrophy. Five aged vervets were immunized with Abeta peptide over 10 months. Plasma and cerebral spinal fluid (CSF) samples were collected periodically from the immunized vervets and five aged controls; one monkey per group expired during the study. By Day 42, immunized animals generated plasma Abeta antibodies that labeled Abeta plaques in human, AD transgenic mouse and vervet brains; bound Abeta1-7; and recognized monomeric and oligomeric Abeta but not full-length amyloid precursor protein nor its C-terminal fragments. Low anti-Abeta titers were detected in CSF. Abetax-40 levels were elevated approximately 2- to 5-fold in plasma and decreased up to 64% in CSF in immunized vervets. Insoluble Abetax-42 was decreased by 66% in brain homogenates of the four immunized animals compared to archival tissues from 13 age-matched control vervets. Abeta42-immunoreactive plaques were detected in frontal cortex in 11 of the 13 control animals, but not in six brain regions examined in each of the four immunized vervets. No T cell response or inflammation was observed. Our study is the first to demonstrate age-related Abeta deposition in the vervet monkey as well as the lowering of cerebral Abeta by Abeta vaccination in a non-human primate. The findings further support Abeta immunotherapy as a potential prevention and treatment of AD.  (+info)

Clearing tau pathology with Abeta immunotherapy--reversible and irreversible stages revealed. (3/58)

The report by Oddo and colleagues in this issue of Neuron demonstrates for the first time that clearance of amyloid also results in the removal of early-stage tau pathology in mice that develop both amyloid plaques and neurofibrillary tangles (NFT), the two hallmark lesions of Alzheimer's disease (AD). This result supports a primary role for Abeta in AD etiology.  (+info)

Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. (4/58)

Amyloid-beta (Abeta) plaques and neurofibrillary tangles are the hallmark neuropathological lesions of Alzheimer's disease (AD). Using a triple transgenic model (3xTg-AD) that develops both lesions in AD-relevant brain regions, we determined the consequence of Abeta clearance on the development of tau pathology. Here we show that Abeta immunotherapy reduces not only extracellular Abeta plaques but also intracellular Abeta accumulation and most notably leads to the clearance of early tau pathology. We find that Abeta deposits are cleared first and subsequently reemerge prior to the tau pathology, indicative of a hierarchical and direct relationship between Abeta and tau. The clearance of the tau pathology is mediated by the proteasome and is dependent on the phosphorylation state of tau, as hyperphosphorylated tau aggregates are unaffected by the Abeta antibody treatment. These findings indicate that Abeta immunization may be useful for clearing both hallmark lesions of AD, provided that intervention occurs early in the disease course.  (+info)

Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. (5/58)

Immunization of amyloid precursor protein transgenic mice with fibrillar beta-amyloid (Abeta) prevents Alzheimer's disease (AD)-like neuropathology. The first immunotherapy clinical trial used fibrillar Abeta, containing the B and T cell self epitopes of Abeta, as the immunogen formulated with QS21 as the adjuvant in the vaccine. Unfortunately, the clinical trial was halted during the phase II stage when 6% of the participants developed meningoencephalitis. The cause of the meningoencephalitis in the patients that received the vaccine has not been definitively determined; however, analysis of two case reports from the AN-1792 vaccine trial suggest that the meningoencephalitis may have been caused by a T cell-mediated autoimmune response, whereas production of anti-Abeta Abs may have been therapeutic to the AD patients. Therefore, to reduce the risk of an adverse T cell-mediated immune response to Abeta immunotherapy we have designed a prototype epitope vaccine that contains the immunodominant B cell epitope of Abeta in tandem with the synthetic universal Th cell pan HLA DR epitope, pan HLA DR-binding peptide (PADRE). Importantly, the PADRE-Abeta(1-15) sequence lacks the T cell epitope of Abeta. Immunization of BALB/c mice with the PADRE-Abeta(1-15) epitope vaccine produced high titers of anti-Abeta Abs. Splenocytes from immunized mice showed robust T cell stimulation in response to peptides containing PADRE. However, splenocytes from immunized mice were not reactivated by the Abeta peptide. New preclinical trials in amyloid precursor protein transgenic mouse models may help to develop novel immunogen-adjuvant configurations with the potential to avoid the adverse events that occurred in the first clinical trial.  (+info)

Current concepts in therapeutic strategies targeting cognitive decline and disease modification in Alzheimer's disease. (6/58)

Alzheimer's disease is a progressive neurodegenerative disorder and the leading cause of dementia in the Western world. Postmortem, it is characterized neuropathologically by the presence of amyloid plaques, neurofibrillary tangles, and a profound gray matter loss. Neurofibrillary tangles are composed of an abnormally hyperphosphorylated intracellular protein called tau, tightly wound into paired helical filaments and thought to impact microtubule assembly and protein trafficking, resulting in the eventual demise of neuronal viability. The extracellular amyloid plaque deposits are composed of a proteinacious core of insoluble aggregated amyloid-beta (Abeta) peptide and have led to the foundation of the amyloid hypothesis. This hypothesis postulates that Abeta is one of the principal causative factors of neuronal death in the brains of Alzheimer's patients. With multiple drugs now moving through clinical development for the treatment of Alzheimer's disease, we will review current and future treatment strategies aimed at improving both the cognitive deficits associated with the disease, as well as more novel approaches that may potentially slow or halt the deadly neurodegenerative progression of the disease.  (+info)

Papillomavirus-like particles are an effective platform for amyloid-beta immunization in rabbits and transgenic mice. (7/58)

Immunization with amyloid-beta (Abeta) prevents the deposition of Abeta in the brain and memory deficits in transgenic mouse models of Alzheimer's disease (AD), opening the possibility for immunotherapy of AD in humans. Unfortunately, the first human trial of Abeta vaccination was complicated, in a small number of vaccinees, by cell-mediated meningoencephalitis. To develop an Abeta vaccine that lacks the potential to induce autoimmune encephalitis, we have generated papillomavirus-like particles (VLP) that display 1-9 aa of Abeta protein repetitively on the viral capsid surface (Abeta-VLP). This Abeta peptide was chosen because it contains a functional B cell epitope, but lacks known T cell epitopes. Rabbit and mouse vaccinations with Abeta-VLP were well tolerated and induced high-titer autoAb against Abeta, that inhibited effectively assembly of Abeta(1-42) peptides into neurotoxic fibrils in vitro. Following Abeta-VLP immunizations of APP/presenilin 1 transgenic mice, a model for human AD, we observed trends for reduced Abeta deposits in the brain and increased numbers of activated microglia. Furthermore, Abeta-VLP vaccinated mice also showed increased levels of Abeta in plasma, suggesting efflux from the brain into the vascular compartment. These results indicate that the Abeta-VLP vaccine induces an effective humoral immune response to Abeta and may thus form a basis to develop a safe and efficient immunotherapy for human AD.  (+info)

Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis. (8/58)

Experiments with amyloid-beta (Abeta)-42-immunized transgenic mouse models of Alzheimer's disease have revealed amyloid plaque disruption and apparent cognitive function recovery. Neuropathological examination of patients vaccinated against purified Abeta-42 (AN-1792) has demonstrated that senile plaque disruption occurred in immunized humans as well. Here, we examined tissue histology and quantified and biochemically characterized the remnant amyloid peptides in the gray and white matter and leptomeningeal/cortical vessels of two AN-1792-vaccinated patients, one of whom developed meningoencephalitis. Compact core and diffuse amyloid deposits in both vaccinated individuals were focally absent in some regions. Although parenchymal amyloid was focally disaggregated, vascular deposits were relatively preserved or even increased. Immunoassay revealed that total soluble amyloid levels were sharply elevated in vaccinated patient gray and white matter compared with Alzheimer's disease cases. Our experiments suggest that although immunization disrupted amyloid deposits, vascular capture prevented large-scale egress of Abeta peptides. Trapped, solubilized amyloid peptides may ultimately have cascading toxic effects on cerebrovascular, gray and white matter tissues. Anti-amyloid immunization may be most effective not as therapeutic or mitigating measures but as a prophylactic measure when Abeta deposition is still minimal. This may allow Abeta mobilization under conditions in which drainage and degradation of these toxic peptides is efficient.  (+info)

*Amyloid beta

Maslow K (Mar 2008). "2008 Alzheimer's disease facts and figures". Alzheimer's & Dementia. 4 (2): 110-33. doi:10.1016/j.jalz. ... One such beta-amyloid vaccine that is currently in clinical trials is CAD106. Aβ42 immunization resulted in the clearance of ... Memantine is an Alzheimer's drug which has received widespread approval. It is a non-competitive N-methyl-D-aspartate (NMDA) ... Zhang S, Iwata K, Lachenmann MJ, Peng JW, Li S, Stimson ER, Lu Y, Felix AM, Maggio JE, Lee JP (Jun 2000). "The Alzheimer's ...

*Alzheimer's disease research

The vaccine AN-1792 showed promise in mouse and early human trials, but in a 2002 Phase II trial, 6% of subjects (18 of 300) ... It has first been noted for the case of insulin insufficiency in the brain of Alzheimer's patients. Because of that Alzheimer's ... Tobinick E (2007). "Perispinal etanercept for treatment of Alzheimer's disease". Curr Alzheimer Res. 4 (5): 550-2. doi:10.2174/ ... therapy with Rember arrests disease progression in mild and moderate Alzheimer's disease over 50 weeks". Alzheimer's & Dementia ...

*List of MeSH codes (D20)

... vaccines MeSH D20.215.894.067 --- alzheimer vaccines MeSH D20.215.894.135 --- bacterial vaccines MeSH D20.215.894.135.063 --- ... measles vaccine MeSH D20.215.894.899.404.500 --- measles-mumps-rubella vaccine MeSH D20.215.894.899.488 --- mumps vaccine MeSH ... hepatitis a vaccines MeSH D20.215.894.899.955.400 --- hepatitis b vaccines MeSH D20.215.894.899.970 --- yellow fever vaccine ... rubella vaccine MeSH D20.215.894.899.779.500 --- measles-mumps-rubella vaccine MeSH D20.215.894.899.790 --- saids vaccines MeSH ...

*Genetically modified tomato

Korean scientists are looking at using the tomato to express a vaccine against Alzheimer's disease. Hilary Koprowski, who was ... "Transgenic tomatoes expressing human beta-amyloid for use as a vaccine against Alzheimer's disease". Biotechnology letters. 30 ... Goyal, R.; Ramachandran, R.; Goyal, P.; Sharma, V. (2007). "Edible vaccines: Current status and future". Indian Journal of ... Tomatoes (along with potatoes, bananas and other plants) are being investigated as vehicles for delivering edible vaccines. ...

*JN-International Medical Corporation

PREVENTIVE AND THERAPEUTIC VACCINE FOR ALZHEIMER'S DISEASE. ... The facility has a targeted production of 10 million doses of vaccine annually. cGMP vaccine facility. cGMP facility inside. ... In January 2009, JNIMC acquired Biocor vaccine manufacture facilities, a subsidiary of Pfizer Inc. in Omaha. The state-of-the- ... ft., and were designed for manufacture of vaccines in compliance with European Community, U.S. Food and Drug Administration and ...

*DMOZ - Health: Conditions and Diseases: Neurological Disorders: Alzheimer's: Research

BBC: Alzheimer's vaccine 'in a patch' A patch to deliver a vaccine against Alzheimer's disease has been shown to be safe. ( ... BBC: Gene 'increases Alzheimer's risk' People born with a certain gene may have a greater risk of developing Alzheimer's, ... BBC: Alzheimer's risk 'is 80% genetic' Genetic factors could determine up to 80% of a person's risk of developing Alzheimer's ... Alzheimer's Disease and Related Disorders Search and Rescue Research Wandering is an important behavior common in Alzheimer's ...

*Synthetic vaccine

... amyloid β peptide vaccine for mild Alzheimer's disease". Alzheimer's & Dementia: Translational Research & Clinical ... Article on synthetic Hib vaccine CRISP Thesaurus entry on Synthetic Vaccines Web Health Centre: History of Vaccines. ... A synthetic vaccine is a vaccine consisting mainly of synthetic peptides, carbohydrates, or antigens. They are usually ... Novartis Vaccine and Diagnostics, among other companies, developed a synthetic approach that very rapidly generates vaccine ...

*Brigham and Women's Hospital

... and starting a clinical trial for a type of Alzheimer's disease vaccine. BWH research also includes population studies ...

*List of vaccine topics

... vaccine Alzheimer's disease amyloid protein vaccine Breast cancer vaccine Ovarian cancer vaccine Prostate cancer vaccine ... vaccine West Nile virus vaccine for humans Zika fever Caries vaccine Ehrlichiosis vaccine Leprosy vaccine Lyme disease vaccine ... vaccine Enterovirus 71 vaccine Epstein-Barr vaccine Hepatitis C vaccine HIV vaccine HTLV-1 T-lymphotropic leukemia vaccine for ... aureus vaccine Streptococcus pyogenes vaccine Syphilis vaccine Tularemia vaccine Yersinia pestis vaccine Malaria vaccine ...

*H. Hugh Fudenberg

One study found that past exposure to influenza vaccine actually decreased the risk of Alzheimer's. In 1995 Fudenberg's medical ... In the 1980s Fudenberg began saying the MMR vaccine causes autism - a fringe position which led to the MMR vaccine controversy ... Scientific consensus concludes that no evidence links the vaccine to the development of autism, and that the vaccine's benefits ... "Past exposure to vaccines and subsequent risk of Alzheimer's disease". Canadian Medical Association Journal. 165 (11): 1495- ...

*Immunologic adjuvant

"Prototype Alzheimer's disease epitope vaccine induced strong Th2-type anti-Aβ antibody response with Alum to Quil A adjuvant ... MF59 is an 'oil [squalene] in water' adjuvant used in some human vaccines. An increasing number of vaccines with squalene and ... "Guideline on Adjuvants in Vaccines for Human Use" (PDF). The European Medicines Agency. Retrieved 8 May 2013. DNA Vaccines: ... PMID 26344622 PMC 4494261/ Baylor N, Egan W, Richman P (2002). "Aluminum salts in vaccines--US perspective". Vaccine. 20 (Suppl ...


... has multiple partnerships around this product to study its effects with vaccines for diseases including Alzheimer's, ... Because each cancer is unique, the vaccine is derived from the patient's own tumor sample. To process these samples, Agenus has ... In October 2013, GlaxoSmithKline and Agenus announced positive data from an 18-month follow-up of GSK's RTS,S malaria vaccine ... The company's personalized, heat shock protein-based vaccines are in Phase 2 studies. The QS-21 Stimulon adjuvant platform is ...

*Jeeri R. Reddy

"PREVENTIVE AND THERAPEUTIC VACCINE FOR ALZHEIMER'S DISEASE", published 25 June 2009 REDDY Jeeri. Preventive and therapeutic ... Method of producing Meningococcal meningitis vaccine for Neisseria meningitides serotypes A, C, Y, and ... development-and-production-low-cost-vaccines A world in which all people at risk are protected against vaccine-preventable ... A notable inexpensive vaccine developed by Reddy is for Meningococcal meningitis for Prevention of Meningitis disease outbreaks ...

*Chang Yi Wang

Site Specific UBITh Amyloid-β Vaccine Amyloid beta for Immunotherapy of Alzheimer's Disease Alzheimer's disease. Vaccine, 2007 ... Site Specific UBITh Amyloid-β Vaccine Amyloid beta for Alzheimer disease, AIDS, and severe Allergic Disease Allergy; and for ... Synthetic AIDS vaccine by targeting HIV receptor. Vaccine 2002, 21: 89-97. 8. Wang, CY, Chang TY, Walfield AM, Ye J, Shen M, ... Synthetic IgE peptide vaccine for immunotherapy for Allergy. Vaccine 2003, 21:1580-1590. 7. Wang, CY, Shen M, Tam G, Fang XD, ...

*Active immunotherapy

Usually with a vaccine. Cancer vaccine C-Met#Active immunotherapy, Alzheimer's disease clinical research#Active immunotherapy, ... Some are vaccines. It divides into: Non-Specific Active Immunotherapy: Generating a general immune system response using ... Mantle cell lymphoma#Immunotherapy, "Heat-shock protein vaccines as active immunotherapy against human gliomas". ...

*Caregiver stress

... and interleukin-10 gene polymorphism on antibody response to tetanus vaccine in family caregivers of patients with Alzheimer's ... "Resources for Enhancing Alzheimer's Caregiver Health (REACH)". Alzheimer's Association. Retrieved 2013-04-03. Span, Paula ( ... Alzheimer's disease and dementia are often used as interchangeable words, but they aren't the same thing. Increasing evidence ... In severe cases of Alzheimer's, caregivers may also take on the symptoms of the patients whom they are taking care of. An ...

*Cytomegalovirus vaccine

For instance, CMV infection is strongly associated with development of Alzheimer's Disease. Development of such a vaccine has ... Other cytomegalovirus vaccines candidates are the CMV-MVA Triplex vaccine and the CMVpp65-A*0201 peptide vaccine. Both vaccine ... A Cytomegalovirus vaccine is a vaccine to prevent cytomegalovirus (CMV) infection or to prevent it re-activation in those who ... As of 2014 no such a vaccine exists, although a number of vaccine candidates are under investigation. They include recombinant ...

*Centre for Research in Neurodegenerative Diseases

... particularly on Alzheimer's disease. The association of late-onset Alzheimer's disease with the Epsilon 4 allele of ... including amyloid vaccines and scyllo-inositol. The Tanz CRND was established in 1990 via philanthropic support from the ... Alzheimer Society of Ontario Tanz Centre for Research in Neurodegenerative Diseases Coordinates: 43°39′37″N 79°23′31″W /  ... In addition, a robust model organism for the amyloid pathology of Alzheimer's disease was created there. The Tanz CRND have ...


It is not known whether reduction of beta-amyloid is a feasible way of treating Alzheimer's, as an anti-beta-amyloid vaccine ... "Alzheimer's may start in liver - Health - Alzheimer's Disease , NBC News". MSNBC. Archived from the original on 5 November 2012 ... As with other immunosuppressants, application of live vaccines is contraindicated because the microorganisms in the vaccine ... Inactivated and toxoid vaccines do not hold this risk, but may not be effective under imatinib therapy. Imatinib was invented ...

*Saint Louis University School of Medicine

Alzheimer's disease, multiple sclerosis, biodefense, influenza, respiratory syncytial virus (RSV) and tuberculosis vaccines. ... Actually, the Saint Louis School of Medicine is one of only eight NIH-funded vaccine research institutions, and made ... neurosciences and vaccine research among others. It is a leading center of research in five key areas: cancer, infectious ... and vaccine development". Effective April 1, 2008, Philip O. Alderson, former chairman of the radiology department at Columbia ...

*Prevention of dementia

... has been theorized that a vaccine could activate the body's own immune system to combat the beta amyloid plaques in Alzheimer's ... "Obesity Today, Alzheimer's Disease Tomorrow?". WebMD. Retrieved 21 March 2016. Eileen M., Welsh (2003). "Focus on Alzheimer's ... "Neuroticism and other personality traits in midlife linked to Alzheimer's risk - Alzheimer's Research UK". 1 October 2014. " ... Some studies say Alzheimer's and other dementias may be caused by high blood pressure, since it can cause blood vessel damage ...

*European Federation of Pharmaceutical Industries and Associations

EFPIA also includes two specialised groups focusing on vaccines and biotechnology respectively: Vaccines Europe (EV) produce ... Yet there remain huge challenges in many disease areas such as Alzheimer, multiple sclerosis, many cancers and orphan diseases ... Vaccines Europe (VE) European Biopharmaceutical Enterprises (EBE) EFPIA on Twitter. ... approximately 80% of vaccines used worldwide. European Biopharmaceutical Enterprises (EBE) harness biotechnology to develop ...

*List of Bulgarian inventors and discoverers

Dimitar Paskov - created the medicine Nivalin, used for the treatment of mild to moderate Alzheimer's disease and various other ... Grigorov made a major contribution to the creation of an anti-tuberculosis vaccine. ...

*Timeline of global health

Timeline of vaccines Timeline of malaria Timeline of HIV/AIDS Timeline of cholera Timeline of influenza Timeline of Alzheimer's ... Offit, Paul A. (2007). The Cutter Incident: How America's First Polio Vaccine Led to the Growing Vaccine Crisis. Yale ... Antitoxins and vaccines for numerous diseases including cholera and tuberculosis are developed during this period, building on ... "Salk produces polio vaccine". PBS. Retrieved June 14, 2016. "History of Salk: About Salk". Retrieved June 14, 2016. ...

*Jackson Laboratory

... vaccines Metabolic diseases: atherosclerosis, cardiovascular disease, diabetes, high blood pressure, obesity Neurobiology: ... blindness, Alzheimer's, deafness, epilepsy, glaucoma, macular degeneration, neurodegenerative diseases Neurobehavioral ...

*DMOZ - Health: Medicine: Research: Institutes, Departments, and Laboratories: Mayo Clinic

Mayo Clinic Alzheimer's Disease Research Provides general information, services offered, staff directory, and free newsletter. ... Mayo Clinic Vaccine Research Group Includes general information, staff directory, services offered, and links. ...
GlaxoSmithKline has signed a deal to get exclusive rights to early-stage vaccines for Alzheimers disease being developed by Affiris, an Austrian biotechnology firm which stands to gain up to 430 million euros. - News - PharmaTimes
The Canada Science and Technology Museum in Ottawa will remain closed for the rest of the year as it deals with the discovery of mould in the buildings south wall.
Free Online Library: Ruthigen Announces First Patient Enrollment in the Phase 1/2 Human Clinical Trial of RUT58-60, a Broad-Spectrum Anti-Infective Drug Candidate Designed for Prophylactic Use During Invasive Surgery. by PR Newswire; Business News, opinion and commentary Antibiotics Product development Clinical trials
In telecommunication, antenna noise temperature is the temperature of a hypothetical resistor at the input of an ideal noise-free receiver that would generate the same output noise power per unit bandwidth as that at the antenna output at a specified frequency. In other words, antenna noise temperature is a parameter that describes how much noise an antenna produces in a given environment. This temperature is not the physical temperature of the antenna. Moreover, an antenna does not have an intrinsic "antenna temperature" associated with it; rather the temperature depends on its gain pattern and the thermal environment that it is placed in. Antenna noise temperature has contributions from several sources: Galactic radiation Earth heating The sun Electrical devices The antenna itself Galactic noise is high below 1000 MHz. At around 150 MHz, it is approximately 1000K. At 2500 MHz, it has leveled off to around 10K. Earth has an accepted standard temperature of 290K. The level of the suns ...
Researchers at the National Institutes of Health are accelerating human clinical trials for what scientists hope is a promising new vaccine to combat the deadly Ebola virus. Phase 1 of the clinical trials, which were previously not expected to begin until the end of September, will start early...
A recently published monkey study showed complete protection in half of the rhesus monkeys included after they were exposed to SIV, a virus similar to HIV ...
Four HBV Product Candidates Advancing In Human Clinical Trials in 1H16 Three IND Filings in 2016 for Oral HBV Drug Candidates Targeting cccDNA, S-Antigen, and Core Protein New Business Unit Established to Maximize Value of Tekmiras Non-HBV Assets VANCOUVER, British … Continue reading →. ...
ProteoTech Inc. (ProteoTech) today announced that it has completed regulatory Investigational New Drug (IND) requirements and has been cleared by the FDA to initiate its Phase 1 human clinical
Angiotech Pharmaceuticals, a Vancouver, BC company, has announced suspension of enrollment in its U.S. and EU human clinical trials for the companys Vascu
The pharmaceutical industry needs better scientific models for testing drugs before they get to the proving ground of human clinical trials. Current lab
Virtual Testing by means of computer simulations of physical models contains a large potential for the improvement of the verification and certification process of an aircrafts high lift system.Rising system complexity (driven by the need for improved A/C efficiency) on one side and shortened development cycles on the other side lead to the need of an extension of the existing, classical test methods.This is why Airbus High Lift Test Department continuously works since a couple of years on the introduction of Virtual Testing as an additional, equivalent test means besides existing, established physical means of compliance such as Test Rigs (TR) and Real Time Simulators, the so called Functional Integration Benches (FIB).Besides the obvious need for highly representative, reliable and efficient computer models, modelling methods and simulation tools this also requires a corresponding Simulation Data- and Process-Management (SDPM), establishing a completely traceable simulation lifecycle ...
Cytokines have important roles in the control of bacterial and viral infections such as HIV-1. Interleukin 17 which is secreted by Th17 is one of these cytokines with a special role in controlling microbial infections. In the present study, adjuvant activity of Alum and Naloxone mixture has been studied on immune responses, especially IL-17 cytokine. Naloxone and Alum adjuvant are mixed with 10 µg of recombinant vaccine HIV-1-gag-pol-tat-env. Experimental groups, consisting of 36 inbred male Balb/c mice divided into six groups, were injected subcutaneouslyat days 0, 14 and 28 with total volume of 200 µl. 2 weeks after final injection, mouse spleens were removed in sterile conditions and used to prepare suspensions. Lymphocyte proliferation responses were evaluated with Brdu test and evaluation of cytokines IL-4, IL-17 and INF-γ were completed using ELISA kit, plus total antibody and antibody isotopes IgG1 and IgG2a using ELISA test. All results show that the mixture of Alum with Naloxone

ACAM2000â ¢: The new smallpox vaccine for United States Strategic  | DDDTACAM2000â ¢: The new smallpox vaccine for United States Strategic | DDDT

... and adverse events associated with this new smallpox vaccine.Keywords: smallpox, vaccinia, variola, vaccine, efficacy, safety ... The previously licensed smallpox vaccine in the United States, Dryvax® (Wyeth Laboratories, Inc.), was highly effective, but ... The US government has therefore recently supported development of an improved live vaccinia virus smallpox vaccine. This ... The new smallpox vaccine for United States Strategic National Stockpile Aysegul Nalca, Elizabeth E ZumbrunCenter for ...
more info

Alzheimers vaccine draws closerAlzheimer's vaccine draws closer

... a recent paper brings us one step closer to developing a vaccine for Alzheimers disease. ... Popular in: Alzheimers / Dementia. * What are the early signs of dementia? * Alzheimers: Death of key brain cells causes ... Alzheimers in women: Could midlife stress play a role? * Could targeting variants of this gene help fight Alzheimers disease ... The hunt for a vaccine. Current treatments for Alzheimers do not stop disease progression, so the search for effective ...
more info

Trial of Alzheimers Vaccine is SuccessfulTrial of Alzheimer's Vaccine is Successful

Alzheimers is a neurological dementia disease in which the body attacks itself destroying brain cells. The disease is on the ... successful trial of a vaccine that helps individuals develop protective antibodies that can prevent progression of Alzheimers ... Home » Disorders » Alzheimers » Trial of Alzheimers Vaccine is Successful. Trial of Alzheimers Vaccine is Successful. By Rick ... The vaccine used in that study activated certain white blood cells (T cells), which started to attack the bodys own brain ...
more info

How Would an Alzheimers Vaccine Work? - Big ThinkHow Would an Alzheimer's Vaccine Work? - Big Think

Could these findings inform efforts to develop a vaccine? ... How Would an Alzheimers Vaccine Work? New research indicates ... Alzheimers disease cannot be transmitted from person to person-it isnt infectious in the way a flu or a common cold spreads- ... "It would be great if at that time of birth or very short afterward if there were a vaccine, an active vaccination that will ... However, if the amyloid beta has benefits in its non-toxic form that scientists have yet to discover, a vaccine against it ...
more info

Scientists test Alzheimers vaccine - Video on NBCNews.comScientists test Alzheimer's vaccine - Video on

Scientists test Alzheimers vaccine. March 11: The results of current clinical trials could mark a major turning point in the ... Art Gives Hope To Alzheimers Patients. NBC News Channel May 28, 2015 ...
more info

Alzheimers Vaccine to Advance to Exploratory Phase Two StudiesAlzheimer's Vaccine to Advance to Exploratory Phase Two Studies

The promising Alzheimers immunotherapy drug AN-1792 has completed the first phase of safety experiments and will soon enter ... These results produced verbal support from organizations such as the Alzheimers Association. "The Alzheimers Association ... the AN-1792 vaccine had been administered to more than 100 patients with mild to moderate Alzheimers disease in a variety of ... and biological markers of Alzheimers disease. Patients with mild to moderate Alzheimers disease will be enrolled and ...
more info

Alzheimers Vaccine Shows Promise - Alzheimers and Dementia Center - Everyday HealthAlzheimer's Vaccine Shows Promise - Alzheimer's and Dementia Center - Everyday Health

A vaccine against Alzheimers disease may soon be on the horizon, say Canadian researchers, who are studying the injection in ... Alzheimers Disease. Alzheimers Vaccine Shows Promise. A vaccine against Alzheimers disease may soon be on the horizon, say ... He says the type of biomarkers his vaccine targets can also be measured in the blood and accurately predict Alzheimers risk. ... The Latest in Alzheimers Disease. Speaking Alzheimers: A Glossary of Common Terms. If you or someone else in your life has ...
more info

GSK signs Alzheimer vaccine deal as CHMP recommends Alli - PharmaTimesGSK signs Alzheimer vaccine deal as CHMP recommends Alli - PharmaTimes

GlaxoSmithKline has signed a deal to get exclusive rights to early-stage vaccines for Alzheimers disease being developed by ... GSK signs Alzheimer vaccine deal as CHMP recommends Alli. 24th October 2008. ... GlaxoSmithKline has signed a deal to get exclusive rights to early-stage vaccines for Alzheimers disease being developed by ... The drug majors GSK Biologicals unit has bought the rights to develop and commercialise two Alzheimers disease vaccine ...
more info

AC Immune gets $22M for tau-targeting Alzheimers vaccine | BioWorldAC Immune gets $22M for tau-targeting Alzheimer's vaccine | BioWorld

AC Immune gets $22M for tau-targeting Alzheimers vaccine By Cormac Sheridan Staff Writer Thursday, January 9, 2014 ... in a Series D round that will fund clinical development of a therapeutic vaccine for Alzheimers disease, ACI-35, which targets ...
more info

Early steps toward an Alzheimers vaccine - Harvard Health Blog - Harvard Health PublishingEarly steps toward an Alzheimer's vaccine - Harvard Health Blog - Harvard Health Publishing

Some encouraging Alzheimers news from Sweden: a vaccine called CAD106 appears to be safe and ramps up the bodys immune system ... Several other Alzheimers vaccines that target the beta amyloid protein are also being tested in clinical trials. Another ... "Its much too early to say whether this particular vaccine will prove to be a valuable treatment in Alzheimers disease," Dr. ... This vaccine work may help answer those questions.. Safety first. In the vaccine study, published online in Lancet Neurology, ...
more info

Alzheimers Vaccine Slows Development of Tangles | Australasian Science MagazineAlzheimer's Vaccine Slows Development of Tangles | Australasian Science Magazine

Attempts to stop Alzheimers disease have focused on preventing the accumulation of amyloid betaplaques associated with the ... A vaccine has proven effective against a neural disease in mice that is considered a model for both Alzheimers disease and ... Alzheimers Vaccine Slows Development of Tangles. By Stephen Luntz. Vaccine shows promise for Alzheimers and early-onset ... A vaccine has proven effective against a neural disease in mice that is considered a model for both Alzheimers disease and ...
more info

San Diego Source > FrontPage > Side Effect Kills Alzheimers Vaccine Candidate; Elan To...San Diego Source > FrontPage > Side Effect Kills Alzheimer's Vaccine Candidate; Elan To...

said it still is pursuing vigorously a vaccine to slow worsening of Alzheimers, and has other candidates that look promising ... WASHINGTON (AP) - The maker of a highly touted experimental Alzheimers vaccine has ended development of the compound after 15 ... But because the vaccine works by inducing the immune system to attack the protein that makes up those plaques, called beta ... the compound code-named AN-1792 could ward off and even reduce brain-clogging plaques that are a hallmark of Alzheimers ...
more info

A mother-and-daughter team have developed what may be the worlds first Alzheimers vaccine. - UpworthyA mother-and-daughter team have developed what may be the world's first Alzheimer's vaccine. - Upworthy

Alzheimers is a terrible disease that robs a person of their personality and memory before eventually leading to death. Its ... The vaccine has synthetic versions of amino acid chains that trigger antibodies to attack Alzheimers protein the blood. Wangs ... A mother-and-daughter team have developed what may be the worlds first Alzheimers vaccine. ... announced the first results from a IIa clinical trial on UB-311 an Alzheimers vaccine. ...
more info

Araclon & TFS to continue partnership, advancing Alzheimers vaccine to Phase IIAraclon & TFS to continue partnership, advancing Alzheimer's vaccine to Phase II

Alzheimers disease is a progressive disease associated with the accumulation, aggregation, and deposition of amyloid beta ( ... Araclon & TFS to continue partnership, advancing Alzheimers vaccine to Phase II. 29 January 2018 , News ... This is a different approach to other AD vaccines, because the immunogen peptide of ABvac40 (Aβx-40) seems to be more relevant ... In the phase I study, the vaccine demonstrated a good safety and tolerability profile and produced an immune response in a high ...
more info

Award-Winning Research Points Toward Targeted Alzheimer s VaccineAward-Winning Research Points Toward Targeted Alzheimer s Vaccine

26, 2011 An accomplice to the protein that causes plaque buildup in Alzheimers disease is the focus of a potential new ... FRONT PAGE Aging Health Alzheimers - Mental Nutrition Medicare & Medicaid Politics Fitness Social Security Alerts Sex Health ... Read the latest news on Alzheimers, Dementia & Mental Health. Unfortunately, all of the vaccines for Alzheimers that have ... Award-Winning Research Points Toward Targeted Alzheimer s Vaccine. Oral vaccine targets RAGE and amyloid by using bodys immune ...
more info

Podcast: Alzheimers Disease Vaccine Trial Suspended on Safety Concern | Medpage TodayPodcast: Alzheimer's Disease Vaccine Trial Suspended on Safety Concern | Medpage Today

CHICAGO, April 18 -- An early phase clinical trial of the investigational Alzheimers disease vaccine ACC-001 was suspended two ... discussed why the development in the ACC-001 study suggested attempts to develop a safe vaccine against Alzheimers disease may ... The vaccine is being developed by Elan and Wyeth. Dr. Cummings reported no relevant conflicts of interest. ... A previous vaccine with the same beta amyloid target was abandoned because of problems with encephalitis. ...
more info

Alzheimers disease vaccine showing promise | American Association for the Advancement of ScienceAlzheimer's disease vaccine showing promise | American Association for the Advancement of Science

It is therefore important to note that this study itself did not assess the ability of the vaccine to treat Alzheimers. ... Vaccines can be thought of as "educators" of our immune system, and by using vaccines we can tell our body to fight particular ... Interestingly, it now appears that the possibility of creating a vaccine for the treatment of Alzheimers disease is also ... This has opened the door for the vaccine to progress to the next phase of study which will ultimately assess the vaccines ...
more info

Vaccine for Alzheimers diseas ( Researchers developing a vaccine agains...)Vaccine for Alzheimer's diseas ( Researchers developing a vaccine agains...)

When Alzheimers mice are vaccinated with beta-amyloid peptide the...,Vaccine,for,Alzheimers,diseas,medicine,medical news ... The vaccines reduces the build-up of protein deposits in mouse bra...Nearly one in ten people over the age of 65 suffers the ... Researchers developing a vaccine against Alzheimers disease have show... ... Vaccine for Alzheimers diseas. Researchers developing a vaccine against Alzheimers disease have show...The vaccines reduces ...
more info

Unique Alzheimers Disease Vaccines Show Great Potential in Pre-Clinical StudiesUnique Alzheimer's Disease Vaccines Show Great Potential in Pre-Clinical Studies

Unique Alzheimers Disease Vaccines Show Great Potential in Pre-Clinical Studies. High Titers Are Achieved Through Proprietary ... Immune sera from animals vaccinated with both anti-tau and anti-AB vaccines, or with a dual vaccine targeting both pathological ... Australia have created a unique vaccine formulation and approach that may overcome historical problems with vaccines against ... "This study suggests that we can immunize patients with early stages of AD with our anti-AB vaccine and, if it progresses, then ...
more info

Comments on Alzheimers Vaccine Shows Promise in MiceComments on Alzheimer's Vaccine Shows Promise in Mice

Latest Alzheimers News MONDAY, Nov. 26, 2018 (HealthDay News) - An experimental Alzheimers disease vaccine shows promise in ... 26, 2018 (HealthDay News) - An experimental Alzheimers disease vaccine shows promise in animal tests, and researchers say it ... In mice created to develop Alzheimers, the vaccine triggered an immune response that reduced accumulation of two toxic ... In mice created to develop Alzheimers, the vaccine triggered an immune response that reduced accumulation of two toxic ...
more info

Will there be a vaccine for Alzheimers? -- Health & Wellness -- Sott.netWill there be a vaccine for Alzheimer's? -- Health & Wellness --

Evidence suggests that Big Pharma is developing a new Alzheimers vaccine to treat Alzheimers and Parkinsons diseases. While ... A vaccine for Alzheimers After the failure to come up with effective drugs, will there be a vaccine for Alzheimers? Evidence ... Alzheimer vaccine R&D Current Alzheimer vaccine R&D stems from 2 theories. The alkaloid cascade hypothesis (ACH) involving a ... Alzheimers vaccine - exploitation and manipulation waiting to happen An Alzheimers vaccine will have a number of advantages ...
more info

Vaccine for Alzheimers disease could become a reality by 2021: scientistsVaccine for Alzheimer's disease could become a reality by 2021: scientists

A new study suggests that a vaccine for the incurable Alzheimers disease could become a reality in as little as five years, ... A woman suffering from Alzheimers desease walks in a corridor on March 18, 2011 in a retirement house in Angervilliers, ...
more info

Dr. Roger Rosenberg leads research of Alzheimers DNA vaccine: Department of Neurology - UT Southwestern, Dallas, TXDr. Roger Rosenberg leads research of Alzheimer's DNA vaccine: Department of Neurology - UT Southwestern, Dallas, TX

Roger Rosenberg shows the potential of a new DNA vaccine in the fight against Alzheimers Disease. The vaccine prompts an ... Roger Rosenberg drives research of Alzheimers DNA vaccine. June 06, 2017. Media Contact :Newsroom ... associated with Alzheimers disease, without causing the severe brain swelling seen in some patients of earlier antibody ... Brain Institute demonstrate in animals how a vaccine containing DNA of the toxic beta-amyloid protein elicits a different ...
more info

Can This Vaccine Reverse Alzheimers? | NeuroscienceCan This Vaccine Reverse Alzheimer's? | Neuroscience

... a drug to treat Alzheimers disease (AD) has yet to be foun , Neuroscience ... It targets the sticky beta-amyloid proteins that accumulate in the brains of patients with Alzheimers. As the disease ... Despite thousands of research studies and millions of dollars dedicated to clinical trials, a drug to treat Alzheimers disease ... Aducanumab is an investigational compound being developed for the treatment of Alzheimers disease. Its a human recombinant ...
more info

UC Irvine Achieves Brain Plaque Vaccine for Alzheimers - New UniversityUC Irvine Achieves Brain Plaque Vaccine for Alzheimer's - New University

UC Irvine Achieves Brain Plaque Vaccine for Alzheimers. April 14, 2008. Jamie Hahlbohm ... believes this is a building block to find an effective treatment for Alzheimers.. "Now we know that the vaccine is very ... An Alzheimers treatment study completed by UC Irvine researchers after two-and-a-half-years concluded that beta-amyloid ... "I believe it is important to test Alzheimer therapies in a higher animal models such as the beagle. However, there are benefits ...
more info
  • Affitope allows the design of proteins with "very specific binding characteristics that are ideally suited for the development of vaccines against disease-causing `rogue' human proteins", the firms added. (
  • However, there are other examples of intracellular proteins that have been targeted for vaccines, and we're not the only ones to get it to work. (
  • Vaccines can be thought of as "educators" of our immune system, and by using vaccines we can tell our body to fight particular regions on proteins -- a skill that matures in its specificity and effectiveness over time. (
  • By using vaccines it is therefore theoretically possible to target these proteins for destruction and subsequently slow the progression of the disease. (
  • Vaccines in animal models have shown effectiveness in reducing amyloid proteins, but a previous trial in humans was unsuccessful as safety concerns arose when patients began to develop meningoencephalitis - a life threatening condition. (
  • In a recent study published by The Lancet Neurology , the tolerability and safety of a newly designed vaccine against amyloid proteins was assessed and demonstrated no significant side effects. (
  • OCEANSIDE, CA --(Marketwired - July 05, 2016) - Capo Therapeutics, Inc., announced today that researchers at The Institute of Molecular Medicine in Huntington Beach, CA, along with collaborators at the University of California at Irvine, Irvine, CA and at Flinders University in Adelaide, Australia have created a unique vaccine formulation and approach that may overcome historical problems with vaccines against the proteins which drive Alzheimer's Disease (AD). (
  • We were able to generate some antibodies in all patients, which is unusual for vaccines,"Yi told Wired. (
  • Unfortunately, the majority of active vaccines targeting AB pathology have failed in clinical trials likely because (i) they were not initiated as early as possible in people who are at AD risk, are prodromal, or have mild AD and (ii) they were not successful at inducing therapeutically potent concentrations of anti-AB antibodies. (
  • Furthermore, Dr. Agadjanyan said, "Any vaccine will not be effective if it is not inducing therapeutically potent concentrations of antibodies. (
  • United Biomedical was a company with only a few hundred employees and yet it was involved in animal and human healthcare: making generic drugs, monoclonal antibodies, blood tests for HIV and vaccines for foot-and-mouth disease. (
  • By creating a vaccine that stimulates the body to make antibodies against Interleukin 17 itself," explains Dr. Foerster, "we can replace the need for frequent and expensive injections. (
  • In a mouse model of Alzheimer's disease, the vaccine increased levels of certain antibodies that are believed to protect against the neurodegenerative disease. (
  • More specifically, the vaccine raised levels of the Immunoglobulin G antibodies that are thought to recognize and fight against aggregates of beta-amyloid plaque in the brain - which is a marker of Alzheimer's disease. (
  • Cashwise, GSK will make an upfront payment of 22.5 million euros and also has an option to develop other vaccines in preclinical development. (
  • An additional important aspect," Prof. Bachmann concludes, "is that we developed a platform technology and are currently broadening our preclinical studies to vaccines against Parkinson's disease as well as chronic pain. (
  • Alzheimer''s disease is a progressive neurodegenerative disease affecting memory and thinking and making the person increasingly dependent on others. (
  • But Elan Corp. said it still is pursuing vigorously a vaccine to slow worsening of Alzheimer's, and has other candidates that look promising in animal testing. (
  • The vaccine is being developed by Elan and Wyeth. (
  • The pharmaceutical company Elan, based in Dublin, Ireland, is poised to begin human clinical trails of a potential treatment based on the vaccine. (
  • It would be great if at that time of birth or very short afterward if there were a vaccine, an active vaccination that will protect us," says Dr. Arancio. (
  • Childhood vaccination has saved many lives, yet lots more has to be done to increase awareness and eliminate myths regarding vaccines. (
  • The results boost hopes that such vaccines could delay or prevent similar symptoms in people. (
  • The company has several other variations of the AN-1792 vaccine in the pipeline, and it hopes to test them in patients soon. (
  • A new vaccine has been found effective against Alzheimer's, bringing hopes for those suffering from the debilitating and complex conditions of the disease. (
  • This study suggests that we can immunize patients with early stages of AD with our anti-AB vaccine and, if it progresses, then vaccinate with our anti-tau vaccine," says Dr. Michael Agadjanyan, Professor and Head of Immunology at the Institute for Molecular Medicine and faculty at the Institute for Memory Impairments and Neurological Disorders, UCI, and one of the senior authors of the study. (
  • In the phase I study, the vaccine demonstrated a good safety and tolerability profile and produced an immune response in a high percentage of patients. (
  • So it is unlikely that this is the main mechanism by which the vaccine reduces amyloid pathology, notes David M. Holtzman, a neurologist at the Washington University School of Medicine. (
  • The vaccine used in that study activated certain white blood cells (T cells), which started to attack the body's own brain tissue. (
  • The results obtained indicate that the vaccine is well tolerated and that a portion of patients developed a sufficient immunological response to AN-1792 to warrant the initiation of the additional study. (
  • In this exclusive MedPage Today podcast, Jeffrey Cummings, M.D., of the University of California Los Angeles, an Alzheimer's specialist not involved in the trial, discussed why the development in the ACC-001 study suggested attempts to develop a safe vaccine against Alzheimer's disease may be more difficult than expected. (
  • It is therefore important to note that this study itself did not assess the ability of the vaccine to treat Alzheimer's. (
  • The next step after this Phase 1 safety trial should be a larger test, possibly with modifications of the dose, to see if the vaccine works, says the study. (
  • 2. Unlike drugs, the Big Pharma manufacturers are not legally obligated to pay out for damages resulting from the adverse effects of vaccines. (
  • The vaccine court establishment will only award payouts in cases involving serious adverse reactions from vaccines. (
  • Rivest says other vaccines in research stage have been ineffective, and one was found to cause inflammation of the brain. (
  • WASHINGTON (AP) - The maker of a highly touted experimental Alzheimer's vaccine has ended development of the compound after 15 patients suffered serious brain inflammation. (
  • According to Reese, the company's ultimate goal is to create a host of vaccines that will be administered to protect people from chronic illness. (
  • There is not much legal aid being made available for those people seeking tort remuneration from vaccine damage. (
  • This approach may be especially beneficial in the elderly because the vaccine utilizes memory T cells that are in abundance in elderly patients instead of relying on activation of naive T cells, which decline with age. (
  • While this treatment stands to bring in blockbuster drug revenue, there are other advantages for Big Pharma which could lead to much exploitation and manipulation for those receiving the vaccine, as will be explained later. (